A5001770042- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Bladder and Urothelial Cancer Treatments
- Endometrial and Cervical Cancer Treatments
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Neutropenia and Cancer Infections
- Urinary and Genital Oncology Studies
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- PI3K/AKT/mTOR signaling in cancer
- Nonmelanoma Skin Cancer Studies
- Gyrotron and Vacuum Electronics Research
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- Lymphoma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cutaneous Melanoma Detection and Management
- Cutaneous lymphoproliferative disorders research
Azienda Ospedaliero-Universitaria Careggi
2022-2024
University of Florence
2022-2024
Despite being early-stage tumors, thin cutaneous melanomas contribute significantly to mortality and have a rising incidence. A retrospective case–control study was performed identify clinical–dermoscopic histopathological variables linked local distant metastases in ≤0.8 mm. Data from 1 January 2000 22 June 2022 were analyzed two Italian skin cancer referral centers. Sixteen patients with mm developing studied compared controls without over 5 years. Statistical analysis involved Pearson’s...
Colorectal cancer (CRC) is the third most common worldwide, with approximately 1.9 million new diagnoses and 935 000 deaths annually. Overall, there accumulating evidence that receiving all available treatments leads to a survival advantage and, although tailored might be appropriate for selected patients, one-size-fits-all approach still widely used in chemo-refractory patients. Currently, different antiangiogenics multitarget agents are indicated treatment of metastatic CRC (mCRC) whereas...
e21144 Background: Immune Checkpoint Inhibitors (ICIs) changed the algorithm of treatment for Non-Small Cell Lung Cancer (NSCLC). Consequently, an increased incidence specific immune-related adverse events (irAEs) were reported, although a clear relationship between toxicity and response to ICIs was not identified. To date no strong predictive factor are univocally recognized in NSCLC. Methods: This is observational, retro-prospective, monocentric study aimed evaluate, patients (pts) with...
Globally, more than 1 million new cases of gastric cancer were estimated in 2020, ranking fourth mortality. Currently although resectable and esophagogastric junction (EGJ) adenocarcinoma a perioperative triplet chemotherapy regimen including fluoropyrimidine, platinum compound docetaxel (FLOT) demonstrated better overall survival, the survival rate is still very low, massive effort required to improve clinical prognosis. High microsatellite instability (MSI-H) status favorable prognostic...